August 2020, Drugs Monitor, Page 4

(02 Aug 2020) Tocilizumab- No impact on mortality in severe COVID-19 patients

August 4, 2020

Impact of tocilizumab administration on mortality in severe COVID-19 https://doi.org/10.1101/2020.07.30.20114959 A total of 132 patients were included in the matched dataset (tocilizumab=66; standard of care=66). Approximately 73% of the patients were male. Hypertension (55%), diabetes mellitus (31%), and chronic pulmonary… Continue reading "(02 Aug 2020) Tocilizumab- No impact on mortality in severe COVID-19 patients"

(01 Aug 2020) Lopinavir/Ritonavir- a high frequency of DDI between LPV-r for treating COVID-19

August 4, 2020

High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment https://doi.org/10.1101/2020.07.30.20165027 Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI: 69%-85%) patients,… Continue reading "(01 Aug 2020) Lopinavir/Ritonavir- a high frequency of DDI between LPV-r for treating COVID-19"

(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality

August 1, 2020

Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 https://doi.org/10.1101/2020.07.24.20153833 To preliminary assess the effect of itolizumab (CT-RPCEC00000311), a control group was selected among the Cuban COVID-19 patients, which did not receive immunomodulatory therapy. Control… Continue reading "(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality"

(30 July 2020) Tocilizumab- not associated with reduced 30-day all-cause mortality, but shorter duration on ventilatory support

August 1, 2020

The study aimed to observe the impact of the IL-6 receptor antagonist tocilizumab on the outcome of patients admitted to the intensive care unit (ICU) with acute respiratory distress syndrome (ARDS) related to COVID-19. Eighty-seven patients with confirmed SARS-CoV-2 infection… Continue reading "(30 July 2020) Tocilizumab- not associated with reduced 30-day all-cause mortality, but shorter duration on ventilatory support"

(30 July 2020) Tocilizumab- earlier use beneficial for survival, length of hospitalization, and duration of oxygen support

August 1, 2020

Appropriate use of Tocilizumab in COVID-19 Infection https://www.ijidonline.com/article/S1201-9712(20)30580-4/fulltext In total, 43 patients were included; 70% of the patients was male; the median age was 64 (min-max: 27-94), 6 (14%) patients were fatal. The median duration of oxygen support before the… Continue reading "(30 July 2020) Tocilizumab- earlier use beneficial for survival, length of hospitalization, and duration of oxygen support"

Month: August 2020

(02 Aug 2020) Tocilizumab- No impact on mortality in severe COVID-19 patients

(01 Aug 2020) Lopinavir/Ritonavir- a high frequency of DDI between LPV-r for treating COVID-19

(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality

(30 July 2020) Tocilizumab- not associated with reduced 30-day all-cause mortality, but shorter duration on ventilatory support

(30 July 2020) Tocilizumab- earlier use beneficial for survival, length of hospitalization, and duration of oxygen support